Papillomavirus humains : dépistage et prévention

McBride, 2017, Oncogenic human papillomaviruses, Philos Trans R Soc Lond B Biol Sci., 372, 20160273, 10.1098/rstb.2016.0273 de Villiers, 2013, Cross-roads in the classification of papillomaviruses, Virology, 445, 2, 10.1016/j.virol.2013.04.023 Human Papillomaviruses, 2012, RC Monographs on the Evaluation of Carcinogenic Risks to Humans, 100B, 255 Egawa, 2017, The low-risk papillomaviruses, Virus Research, 231, 119, 10.1016/j.virusres.2016.12.017 de Sanjosé, 2018, The natural history of human papillomavirus infection, Best Pract Res Clin Obstet Gynaecol, 47, 2, 10.1016/j.bpobgyn.2017.08.015 Liu, 2016, Penise not required : a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration, Sex Health., 13, 10, 10.1071/SH15089 Gavillon, 2010, Papillomavirus humain (HPV) : comment ai-je attrapé ça ? [How did I contract human Papillomavirus (HPV)?], Gynecol Obstet Fertil, 38, 199, 10.1016/j.gyobfe.2010.01.003 Giuliano, 2015, EUROGIN 2014 roadmap : differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection, Int J Cancer, 136, 2752, 10.1002/ijc.29082 Lu, 2012, Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men, Cancer Res, 72, 676, 10.1158/0008-5472.CAN-11-0751 Schiffman, 2016, Carcinogenic human papillomavirus infection, Nat Rev Dis Primers, 2, 16086, 10.1038/nrdp.2016.86 Bruni, 2010, Cervical human papillomavirus prevalence in 5 continents : meta-analysis of 1 million women with normal cytological findings, J Infect Dis, 202, 1789, 10.1086/657321 Guan, 2012, Human papillomavirus types in 115,789 HPV-positive women : a meta-analysis from cervical infection to cancer, Int J Cancer, 131, 2349, 10.1002/ijc.27485 Mena, 2019, Might Oral Human Papillomavirus (HPV) Infection in Healthy Individuals Explain Differences in HPV-Attributable Fractions in Oropharyngeal Cancer? A Systematic Review and Meta-analysis, J Infect Dis, 219, 1574, 10.1093/infdis/jiy715 de Martel, 2017, Worldwide burden of cancer attributable to HPV by site, country and HPV type, Int J Cancer., 141, 664, 10.1002/ijc.30716 he Bethesda system for reporting cervical cytology, Nayar & Wilbur 2015. Stoler, 2014, 172 Mirghani, 2019, Prevalence and characteristics of HPV-driven oropharyngeal cancer in France, Cancer Epidemiol, 61, 89, 10.1016/j.canep.2019.05.007 Décision du 4 mars 2020 de l’Union nationale des caisses d’assurance maladie relative à la liste des actes et prestations pris en charge par l’assurance maladie, NOR : SSAU2007870S, JO du 25 mars 2020. Évaluation de la recherche des papillomavirus humains (HPV) en dépistage primaire des lésions précancéreuses et cancéreuses du col de l’utérus et de la place du double immuno-marquage p16/Ki67, Recommandation en Santé Publique, HAS, juillet 2019. Conduite à tenir devant une femme ayant une cytologie cervico-utérine anormale, Collection recommandations et référentiels, INCa, décembre 2016. Surveillance post-thérapeutique des lésions précancéreuses du col de l’utérus, Collection recommandations et référentiels, INCa, septembre 2019. Poljak, 2020, Commercially available molecular tests for human papillomaviruses : a global overview, Clin Microbiol Infect, 26, 1144, 10.1016/j.cmi.2020.03.033 Arbyn, 2016, VALGENT : A protocol for clinical validation of human papillomavirus assays, J Clin Virol, 76, S14, 10.1016/j.jcv.2015.09.014 Garland, 2016, Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine : A Systematic Review of 10 Years of Real-world Experience, Clin Infect Dis, 63, 519, 10.1093/cid/ciw354 Machalek, 2018, Very Low Prevalence of Vaccine Human Papillomavirus Types Among 18- to 35-Year Old Australian Women 9 Years Following Implementation of Vaccination, J Infect Dis, 217, 1590, 10.1093/infdis/jiy075 Patel, 2018, The impact of 10 years of human papillomavirus (HPV) vaccination in Australia : what additional disease burden will a nonavalent vaccine prevent?, Euro Surveill, 23, 1700737, 10.2807/1560-7917.ES.2018.23.41.1700737 Lei, 2020, HP Vaccination and the Risk of Invasive Cervical Cancer, N Engl J Med., 383, 1340, 10.1056/NEJMoa1917338 Malagón, 2012, Cross-protective efficacy of two human papillomavirus vaccines : a systematic review and meta-analysis, Lancet Infect Dis, 12, 781, 10.1016/S1473-3099(12)70187-1 Castellsagué, 2015, Immunogenicity and safety of the 9-valent HPV vaccine in men, Vaccine, 33, 6892, 10.1016/j.vaccine.2015.06.088 Joura, 2015, Broad Spectrum HPV Vaccine Study, A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med, 372, 711 Grimaldi-Bensouda, 2017, PGRx-AD Study Group. Risk of autoimmune diseases and human papilloma virus (HPV) vaccines : Six years of case-referent surveillance, J Autoimmun, 79, 84, 10.1016/j.jaut.2017.01.005 Verdoodt, 2020, Dose-related effectiveness of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia: A Danish nationwide cohort study, Clin Infect Dis., 70, 608 Markowitz, 2020, Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses, J Infect Dis, 221, 910, 10.1093/infdis/jiz555 Giuliano, 2011, Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males, N Engl J Med, 364, 401, 10.1056/NEJMoa0909537 Palefsky, 2011, HPV vaccine against anal HPV infection and anal intraepithelial neoplasia, N Engl J Med, 365, 1576, 10.1056/NEJMoa1010971 Olsen, 2015, Revisiting the cost-effectiveness of universal HPV-vaccination in Denmark accounting for all potentially vaccine preventable HPV-related diseases in males and females, Cost Eff Resour Alloc, 13, 4, 10.1186/s12962-015-0029-9